Research programme: inositol trisphosphate receptor antagonists - Innovatis Pharma CorporationAlternative Names: IP 1002E
Latest Information Update: 07 Mar 2011
At a glance
- Originator Innovatis Pharma Corporation
- Mechanism of Action Inositol 1,4,5 trisphosphate receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 12 Jul 2006 Preclinical trials in Cancer in Japan (unspecified route)